Stents Drug Eluting

This channel includes news and new technology innovations for drug eluting stents (DES). These drug coated stents were developed to solve a frequent problem with bare metal stents, which can cause neointimal hyperplasia (scar tissue growth) in some patients. The antiproliferative drugs used on DES prevent the growth of tissue. One downside of DES is the requirement for patients to take long-term antiplatelet therapy to prevent the possible formation of clots on these stents. Newer generation DES use technologies help the vessels heal faster, which may allow reduce the duration of dual antiplatelet therapy (DAPT), or use a single drug, usually eliminating aspirin. This section includes news for both metallic and bioresorbable drug-eluting stents and related clinical trial data.

stents, Cobra, celonova

CeloNova Stent

News | November 25, 2014
November 25, 2014 — CeloNova BioSciences, Inc., announced that positive frst-in-man (FIM) clinical trial results found...
DAPT study
Feature | November 18, 2014
November 18, 2014 — Patients who took dual antiplatelet therapy medications beyond the standard 12 months after...
News | November 13, 2014
Nov. 13, 2014 — Optimizing the treatment of coronary artery disease with a new foundation for future stent innovations...
Technology | November 04, 2014
November 4, 2014 — The U.S. Food and Drug Administration (FDA) has cleared the Abbott family of Xience everolimus-...
News | October 20, 2014
October 20, 2014 — Boston Scientific Corp. has initiated the PLATINUM Diversity trial to evaluate the clinical...
News | September 26, 2014
September 26, 2014 — A first-of-its kind study comparing the safety and efficacy of biodegradable polymer sirolimus-...
Svelte Coronary DES DIRECT II Trial Six Month Results TCT 2014
News | September 25, 2014
September 25, 2014 — Svelte Medical Systems reported that its drug-eluting coronary stent Integrated Delivery System (...
bioresorbable stents, dissolving stents, Absorb stent, BVS

Abbott has spearheaded bioresorbable stent technology with the development with its BVS. By far the BVS has the most clinical experience, with more than 13,000 patients around the world having been treated with the device.

Feature | Stents Bioresorbable | September 03, 2014 | Dave Fornell
(UPDATE: read the Sept. 8, 2017 article "Abbott Will End Sales of Absorb Bioresorbable Stent")   A key prediction for...
Patient Enrollment REDUCE Sudy Combo Dual Therapy Stent OrbusNeich
News | August 15, 2014
August 15, 2014 — OrbusNeich announced first patient enrollment in the Randomized Evaluation of short-term Dual anti...
News | July 30, 2014
July 30, 2014 — OrbusNeich announced the first patient has been enrolled in the Multinational Abluminal Sirolimus...
News | July 15, 2014
July 15, 2014 — Micell Technologies Inc. announced the United States Patent and Trademark Office (USPTO) has issued a...
Blog | Cardiovascular Business | July 09, 2014
A big fly in the ointment for widespread adoption of many new technologies is cost. In today’s cost-conscience...
Feature | July 09, 2014
A big fly in the ointment for widespread adoption of many new technologies is cost. In today’s cost-conscience...
OrbusNeich Patient Enrollment Completion REMEDEE Registry Combo Stent
News | June 24, 2014
June 24, 2014 — OrbusNeich announced the completion of enrollment in the prospective, multicenter, all-comers REMEDEE...
News | June 10, 2014
June 10, 2014 — Ariad Pharmaceuticals Inc. and Medinol Ltd. earlier this year initiated two registration trials of...